Donald McCaffrey
Chief Executive Officer chez RESVERLOGIX CORP.
Fortune : 613 356 $ au 31/03/2024
Profil
Donald J.
McCaffrey is the founder.
He founded Resverlogix Corp.
in 2000, where he currently holds the titles of Chairman, President, CEO & Secretary.
He also founded Zenith Capital Corp.
(Alberta) in 2013, where he currently holds the titles of Chairman, President & Chief Executive Officer.
In addition to his founding positions, Mr. McCaffrey has held former positions as Director at Trillium Therapeutics ULC from 2004 to 2006, and as Director at ProMIS Neurosciences, Inc.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
ZENITH CAPITAL CORP.
1,72% | 02/01/2024 | 2 615 324 ( 1,72% ) | 392 299 $ | 31/03/2024 |
RESVERLOGIX CORP.
1,93% | 02/01/2024 | 5 263 266 ( 1,93% ) | 221 057 $ | 31/03/2024 |
Postes actifs de Donald McCaffrey
| Sociétés | Poste | Début |
|---|---|---|
| RESVERLOGIX CORP. | Chief Executive Officer | 25/04/2003 |
| ZENITH CAPITAL CORP. | Chief Executive Officer | 10/04/2013 |
Anciens postes connus de Donald McCaffrey
| Sociétés | Poste | Fin |
|---|---|---|
| TRILLIUM THERAPEUTICS | Director/Board Member | 27/03/2006 |
| PROMIS NEUROSCIENCES, INC. | Director/Board Member | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| RESVERLOGIX CORP. | Health Technology |
| PROMIS NEUROSCIENCES, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Trillium Therapeutics ULC
 Trillium Therapeutics ULC BiotechnologyHealth Technology Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada. | Health Technology |
| Zenith Capital Corp. (Alberta) |
